Sky9 Capital Announces the Addition of Chay, Teh, Xu, and Zeng to its Advisory Board
HONG KONG, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Sky9 Capital, a leading China venture capital firm, announced that China industry veterans KS Chay, Dr. Kok Peng Teh, Bob Xu, and Jason Zeng have joined its Advisory Board to provide strategic advice and foster long-term partnerships.
KS Chay is Founder and Chairman of Enspire Capital, and previously he co-founded Singapore's first Nasdaq-listed technology company, Creative Technology Ltd (SGX:C76). Dr. Kok Peng Teh is currently Senior Advisor and Board Member for China International Capital Corporation, and he was President of Government of Singapore Special Investments (GIC) for over a decade until 2011. Mr. Bob Xu co-founded New Oriental Education & Technology Group (NYSE:EDU), the largest provider of private education in China, and is one of China's most successful angel investors having founded ZhenFund in 2010. Mr. Jason Zeng co-founded Tencent Holdings Ltd (HK:0700) and is currently Chairman of the angel-stage investment firm Decent Capital.
"We are honored to have industry veterans like KS Chay, Dr. Kok Peng Teh, Bob Xu, and Jason Zeng join our firm as our board of advisors," said Ron Cao, Founder and Managing Director of Sky9 Capital. "Mr. Chay and Dr. Teh come from a strong institutional approach to investing and can provide us with great guidance on how to continue to build out our organization. Bob and Jason are two of China's most successful entrepreneurs, so we gain great insights from their operational background as well as inspiration on how to build great businesses together with entrepreneurs."
Founded by China venture capital veteran Ron Cao, Sky9 Capital's mission is to partner with the next generation of entrepreneurs to create world-class companies that also have societal impact. With over 17 years of VC experience in both the US and China, Ron has invested in some of China's leading technology companies including: Tujia, China's largest AirBnB player; FangDuoDuo, China's largest online-to-offline real estate transaction platform; PPDai, China's largest pure-play microlending platform; and QingCloud, China's leading enterprise-grade cloud computing platform. Ron has been named by Forbes China as one of China's "Top Venture Capitalists" over multiple years and is honored by the World Economic Forum as one of its "Young Global Leaders".
Sky9 Capital's senior team consists of additional partners with strong venture capital and start-up experience. The team of Wei Hao, Jing Wang, Jonathan Qiu, and Tony Lo, have collectively over 30 years of venture capital experience in the US and China, and they previously worked at world-class technology companies such as Intel, Trilogy, Cisco, and Tencent. Their investments include PinDuoDuo, FaceU, Rong360, ZhaoGangWang, MaMaDaV, FangDuoDuo, JuMei, JingFuZhi, LuckyPai, and Dianping.
Sky9 Capital has completed six investments in its new fund, including ZhaoYouWang, the largest B2B marketplace for petroleum-related products in China; EZbuy, the leading Chinese cross-border e-commerce platform targeting the Southeast Asia market; and eBroker, the leading online platform for wealth management.
About Sky9 Capital
Sky9 Capital is a leading early-stage China-focused technology venture capital firm. With its mission to partner with bold innovators to build world-class companies together and to make a positive impact on the world, Sky9 Capital specializes in the consumer Internet, enterprise, and deep technology sectors. With presence in Beijing, Shanghai, Shenzhen, and Silicon Valley, our firm approaches investing with a global perspective and selectively partners with early-stage companies that have exceptional founding teams, disruptive and scalable business models, or innovative and transformational technology. For more information, please visit www.sky9capital.com.
Contact: Anthony Lo
Phone Number: +86-21-5238-3699
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sky9 Capital via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Raven Indusries Releases CR12(TM) Field Computer18.6.2018 16:49 | Pressmeddelande
12-Inch Display With Field Planning Features Helps Farmers Save Time and Increase Efficiencies MIDDENMEER, The Netherlands, June 18, 2018 (GLOBE NEWSWIRE) -- Raven Industries (NASDAQ:RAVN) announced today the release of a new, larger field computer: the CR12(TM). Utilizing the same powerful functionality as the CR7(TM) field computer, the CR12 offers an extensive field planning feature for increased efficiencies. Built with a durable magnesium waterproof housing and a full glass capacitive touchscreen with high brightness, the CR12 also boasts a wider, 12.1-inch display. The CR12 joins the CR7 as the latest field computer in the CRX display family. This powerful operating system features easy job set-up, fewer touches and greater efficiencies - empowering the user with extraordinary data management capabilities. A simple widget concept, easily accessible settings, and ISO Universal Terminal and Task Controller capabilities make this mighty unit an affordable, plug-and-play system. Like
FPGA programming solution goes live at AEE 2018 in latest version of SLX18.6.2018 15:00 | Pressmeddelande
Silexica / FPGA programming solution goes live at AEE 2018 in latest version of SLX . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Industry-first solution fully explores the design space to optimize hardware/software partitioning SLX automatically inserts pragmas and rewrites code to make it High-Level Synthesis (HLS) ready Solution designed in collaboration with customers including Ricoh SAN JOSE, Calif. and COLOGNE, Germany, June 18, 2018 (GLOBE NEWSWIRE) -- Silexica will launch a new solution within SLX to support the increasing use of FPGAs for embedded computing tasks such as sensor fusion and deep learning. It has been developed in partnership with Ricoh and other customers who will use the solution for industrial automation and defense projects. The technology will be presented at Silexica's first appearance one of the world's biggest avionics exhibitions - AEE held in Munich from June 19-20. The
Immunicum AB (publ) meddelar publicering av en översiktsartikel kring ilixadencel-konceptet i Pharmaceutical Research18.6.2018 14:00 | Pressmeddelande
Pressmeddelande 18 juni 2018 Immunicum AB (publ) meddelar publicering av en översiktsartikel kring ilixadencel-konceptet i Pharmaceutical Research Immunicum AB (publ; IMMU.ST) offentliggjorde i dag online-publiceringen av en översiktsartikel av den senaste tidens utveckling inom immunonkologiforskning, med särskilt fokus på tidigare publicerade data som stöder värdet av bolagets ledande program, ilixadencel. Artikeln, med titeln "Ilixadencel - An Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration" publicerades on-line i Pharmaceutical Research , American Association of Pharmaceutical Scientists officiella tidskrift. Artikeln finns via följande länk https://link.springer.com/article/10.1007/s11095-018-2438-x - Det är en ära för vårt forsknings- och utvecklingsteam på Immunicum att bli erbjudna att skriva denna omfattande översikt som tar upp ilixadencels verkningsmekanism mot bakrund av de senaste upptäckterna gällande immunaktivering mot cancer. Våra preklin
Goldman Sachs and Cisco to Host Tech Talk on Data Center Networking18.6.2018 14:00 | Pressmeddelande
SAN JOSE, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Cisco will host a conference call with Goldman Sachs and Cisco's Ish Limkakeng, SVP, Product Management, Data Center Networking Group. The discussion will focus on Cisco's data center networking strategy, comprehensive portfolio, and its competitive advantage as customers seek highly secure and differentiated offerings. Interested parties can find more information on Cisco's Investor Relations website at https://investor.cisco.com. No new financial information will be discussed on this conference call. Date: Thursday, June 21, 2018 Time: 8:30 am PT / 11:30 am ET Speaker: Ish Limkakeng, SVP, Product Management, Data Center Networking Group Moderator: Goldman Sachs' Rod Hall, Managing Director Participant Dial in: Toll Free: 877-208-2954 International Number: 973-528-0056 Passcode: 201872 Replay Information (available until July 5, 2018): Toll Free: 800-332-6854 International Number: 973-528-0005 Passcode: 201872 This event will be webc
Immunicum AB (publ) Announces Publication of Scientific Review of Ilixadencel Approach in Pharmaceutical Research18.6.2018 14:00 | Pressmeddelande
Press Release 18 June 2018 Immunicum AB (publ) Announces Publication of Scientific Review of Ilixadencel Approach in Pharmaceutical Research Immunicum AB (publ; IMMU.ST) announced today the online publication of a review article providing an overview of recent developments in immuno-oncology research, specifically focusing on previously published data supporting the value of its lead program, ilixadencel. The article, titled "Ilixadencel - An Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration", was published in Pharmaceutical Research , the official journal of the American Association of Pharmaceutical Scientists. The article can be accessed via the following link https://link.springer.com/article/10.1007/s11095-018-2438-x "It is an honor for our research and development team at Immunicum to be invited to write this in-depth review article covering ilixadencel's mode of action in context of the most recent discoveries in anti-cancer immune activation," comme
DSM Sinochem Pharmaceuticals launches Atorvastatin film-coated tablets, expanding its finished dosage statins portfolio18.6.2018 11:23 | Pressmeddelande
Rijswijk, 18 June 2018, June 18, 2018 (GLOBE NEWSWIRE) -- Building upon its first generic finished dosage statin launch (Rosuvastatin) in January of this year, DSM Sinochem Pharmaceuticals (DSP) has this month released its fully backward-integrated, generic Atorvastatin drug product within the EU. Additional markets are scheduled to follow later in the year.Atorvastatin is used primarily in the prevention of cardiovascular disease and hyperlipidemia, commonly known as high cholesterol, the number one cause of death worldwide. Currently, statins are the most prescribed drug family globally in the fight against these potentially life-threatening conditions. Expanding statins portfolio With the launch now of Atorvastatin finished dosage formulation, coming on the heels of the successful launch of Rosuvastatin in January of 2018, DSP is actively expanding its statins drug product portfolio, realizing its aspiration of becoming a full-service generics pharmaceutical company. What sets DSP a
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum